(Reuters) - Anemia drugs known as erythropoiesis-stimulating agents, or
ESAs, are sold by Amgen Inc. as Epogen and Aranesp and
by Johnson & Johnson as Procrit.
"In response to safety concerns, we are modifying the ESA
monitoring policy to provide greater restrictions on the dosage
amounts of ESAs for which payment is made" for patients with
hemoglobin levels above 13 grams per deciliter, the Centers for
Medicare & Medicaid Services said in a statement.
Read more at Reuters.com Government Filings News
ESAs, are sold by Amgen Inc. as Epogen and Aranesp and
by Johnson & Johnson as Procrit.
"In response to safety concerns, we are modifying the ESA
monitoring policy to provide greater restrictions on the dosage
amounts of ESAs for which payment is made" for patients with
hemoglobin levels above 13 grams per deciliter, the Centers for
Medicare & Medicaid Services said in a statement.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment